NDAINTRAVENOUSSOLUTION
Approved
Feb 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
5/8 — Partial
PARSABIV (etelcalcetide) by Lavipharm is calcium-sensing receptor (casr). Approved for secondary hyperparathyroidism, chronic kidney disease, end stage renal disease. First approved in 2017.
Drug data last refreshed 20h ago
Mechanism of Action
calcium-sensing receptor (CaSR). Etelcalcetide binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.
Indications (3)
Worked on PARSABIV at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.